Diabetes Core Update

In this special episode of The Points of CARE, recorded live during the American Diabetes Association's (ADA) 2026 Scientific Sessions in New Orleans, hosts Richard Beaser, MD and Jane Reusch, MD highlight a new symposium on the clinical, social, and economic costs of treating—or not treating—individuals with obesity. This panel discussion is moderated by Louis J. Aronne, MD, Sanford I. Weill Professor of Metabolic Research at Weill-Cornell Medical College in New York, former president of the Obesity Society, and chair emeritus of the American Board of Obesity Medicine. Presenters: Timothy Dall, MS Managing Director for Life Sciences Consulting at GlobalData Melanie R. Jay, MD, Professor of Medicine and Population Health at the New York University Grossman School of Medicine Catherine Ferguson, MA, Vice President of Federal Advocacy for the ADA Featured Articles: The Cost of Inaction in Treating Obesity in the U.S. doi.org/10.2337/doci25-0011 Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans doi.org/10.2337/doci25-0006 Estimating the Health, Economic, and Social Benefits of Obesity Treatment Using Microsimulation Modeling doi.org/10.2337/doci25-0004 For more on the Cost of Obesity collection, visit diabetesjournals.org/collection/26413/Cost-of-Obesity To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Welcome to the latest episode (June 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month on DOC Update: Shah S, et al. "Food Coloring Additives and Incidence of Type 2 Diabetes in the NutriNet-Santé Prospective Cohort Diabetes Care. 2026;49(6):1067–1077. doi.org/10.2337/dc25-2727 Hespanhol L, et al. "Automated Insulin Delivery Systems in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis." Diabetes Care. 2026;49(6):1134–1143. doi.org/10.2337/dc25-2435 Tatum K, et al. "Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer." JAMA. Published Online: May 11, 2026 2026;9;(5):e2612133. doi:10.1001/jamanetworkopen.2026.12133 Winkler C, et al. "Screening Children for Early-Stage Type 1 Diabetes." JAMA. Published Online: May 21, 2026 doi:10.1001/jama.2026.6085 Würtz Yazdanfard P, Kosjerina V, Wood-Kurland H et al. "Effectiveness and Safety of Semaglutide in Type 1 Diabetes: A Danish Nationwide Cohort Study (2018–2024)" Lancet. Volume 66, 101716, July 2026. doi:10.1016/j.lanepe.2026.101716 Horn D, Aronne L, Wharton S et al. "Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial." Lancet. Published online May 12, 2026. doi:10.1016/S0140-6736(26)00656-2 Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, click here.

In the first episode of this series on Obesity, our host is joined by Dr. Mikhail Kosiborod to discuss the evolving science and cardiometabolic diseases associated with obesity. This special episode is sponsored with support from AstraZeneca. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Mikhail Kosiborod, MD, Senior Vice President Late-Stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca. Selected references: Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation October 2023

We have only recently become aware of the close relationship between the heart and the kidneys. In today's discussion, Dr. Neil Skolnik speaks with Dr. Josephine Harrington to gain insight into these newly-discovered links between cardiovascular risk and CKD. This special episode is sponsored with support from Bayer. Please listen to the episodes by clicking on the podcast player below or by freely subscribing to Diabetes Core Update via Apple Podcasts, Amazon Music, Spotify, or your preferred podcast platform. Presented by: Neil Skolnik, MD, Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Josephine Harrington, M.D., Assistant Professor of Medicine in the Division of Cardiology at the University of Colorado School of Medicine. Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026. The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1):S246–S260 Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020;383:2219-2229 Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020;383:1436-1446 Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med 2024;391:109-121

Welcome to the latest episode (May 2026) of Diabetes Core Update, where every month Neil Skolnik, MD and John Russell, MD review the most important articles on diabetes, obesity, and cardiometabolic disease. This month, they discuss: Marston NA, Bohula EA, Bhatia AK, et al. "Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Trial." JAMA. 2026;335(16):1400–1407. doi:10.1001/jama.2026.3277 Lee YJ, Lee SJ, Kim JW, et al. "Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease." N Engl J Med 2026;394:1365-1375. doi:10.1056/NEJMoa2600283 Nissen SE, Wolski K, D'Alessio D, et al. "Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial." JAMA Cardiol. Published online March 28, 2026. doi:10.1001/jamacardio.2026.0767 Moura FA, et al. "Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis." Diabetes Care. 2026;49(5):724–729. doi.org/10.2337/dc25-1238 Ostrominski JW, Ortega-Montiel J, et al. "Comparative Effectiveness of Tirzepatide Versus Dulaglutide or Semaglutide on Major Cardiovascular Events in Type 2 Diabetes and Cardiovascular Disease: Insights From Two Target-Trial Emulations." Diabetes Care. 2026;49(5):808–817 doi.org/10.2337/dc25-3063 Nicole Napoli, "Shingles Vaccine Drastically Cuts Risk of Serious Cardiac Events." The American College of Cardiology. March 17, 2026 https://www.acc.org/About-ACC/Press-Releases/2026/03/16/19/33/Shingles-Vaccine-Drastically-Cuts-Risk-of-Serious-Cardiac-Events For information about the American Diabetes Association's scholarly journals, visit diabetesjournals.org. For more about this podcast, visit About Diabetes Core Update.

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 2:30 After introducing his co-host, Jane Reusch, Beaser speaks with James Gavin, MD, PhD, of the Emory University School of Medicine and Naunihal Virdi, MD, MBA, FACP, of Abbott Diabetes Care. They are the authors of "Advancing Type 2 Diabetes Care: The Role of Continuous Glucose Monitoring in Noninsulin-Treated Patients," available for free at doi.org/10.2337/doc25-0058. 13:00 Our hosts are joined by Ivy Shi, MD and Dhruv Kazi, MD, MSc, MS, both of Beth Israel Deaconess Medical Center. They are the authors of "GLP-1 RA Eligibility in Reproductive-Age U.S. Women," available in the March/April issue of Diabetes, Obesity, and CardioMetabolic CARE. 19:40 Next, Eva Tseng, MD, MPH, associate professor of medicine at Johns Hopkins School of Medicine joins the podcast. Her article, "START Diabetes Prevention: A Multilevel Strategy for Primary Care Clinics," is available in the March/April issue of Diabetes, Obesity, and CardioMetabolic CARE. To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

This issue will review: 1. Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide 2. Estimated Optimal Individualized Diabetes Risk Prediction From Preventive Interventions in the U.S. General Population 3. Impact of Metabolic Bariatric Surgery on Weight Loss and Glycemic Control in Adults With Type 1 Diabetes 4. Finerenone in Type 1 Diabetes and Chronic Kidney Disease 5. Effects of Sodium/Glucose Cotransporter-2 Inhibitor Use on Mortality, Amputation, and Healing in Patients With Diabetic Foot Ulcer Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's science and medical journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE, and beyond. Each episode is approximately 25 minutes long and presents recently published articles from ADA journals and more. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

In this special edition on CKD our host, Dr. Neil Skolnik will discuss epidemiology, pathophysiology and screening for CKD in People with Diabetes. This special episode is supported by an independent educational grant from Bayer. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Holly Kramer, M.D., Professor of Public Health Sciences and Medicine in the Division of Nephrology and Hypertension at Loyola University Chicago, past-president of the National Kidney Foundation, Editor-in-Chief of the National Kidney Foundation's journal, Advances in Kidney Disease and Health (AKDH). Selected references: Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 . The American Diabetes Association's Standards of Care 2026, Diabetes Care 2026;49 (Supplement_1) :S246–S260

This issue will review: Real-World Prospective Validation and Economic Evaluation of Deep Learning-Based Diabetic Retinopathy Detection from Fundus Photographs: A Systematic Review and Meta-Analysis. Diabetes Care 2026;49:510–525; An oral small-molecule GLP-1 receptor agonist for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet 2025;406:2929-2944; FDA removal of SI for GLP-1s – FDA Announcement Neil Read/John Comment; Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk: A Target Trial Emulation Study. Ann Intern Med 2025;172:157-167; and GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients with Type 2 Diabetes or Cardiometabolic Diseases: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care 2026;49:526-535. Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's science and medical journals – Diabetes, Diabetes Care, and Diabetes, Obesity, and Cardiometabolic CARE, and beyond. Each episode is approximately 25 minutes long and presents recently published articles from ADA journals and more. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast. The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE, will highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. In this special inaugural episode, host Richard Beaser, MD also discusses the ADA's Obesity Association and the "Standards of Care in Overweight and Obesity." 4:15 Beaser speaks with Alissa Segal, PharmD, RPh, CDCES, CDTC, FCCP. Dr. Segal is editor in chief of Diabetes, Obesity, and CardioMetabolic CARE and professor of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences. Her editorial, "Diabetes, Obesity, and CardioMetabolic CARE: Building New From a Strong Foundation," is available for free at doi.org/10.2337/doci25-0010. 13:00 Samar Hafida, MBCCh, joins the conversation. Dr. Hafida is a board-certified endocrinologist and weight management specialist at Boston Medical Center and assistant professor of medicine (Endocrinology, Diabetes, Nutrition & Weight Management) at the Boston University Chobanian & Avedisian School of Medicine. She is also vice president of the ADA's Obesity Association. Her editorial, "Introducing the Obesity Association and the Launch of Our Official Journal," is available for free at doi.org/10.2337/doci25-0012. 17:55 Dr. Hafida discusses "Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity." This article is available for free at doi.org/10.2337/doci25-0008. 20:05 Richard and Alissa highlight a few articles from the first issue of Diabetes, Obesity, and CardioMetabolic CARE. Simpkins et al. "Association of Type 2 Diabetes Subgroups With Incident Peripheral Neuropathy" doi.org/10.2337/doc25-0051 Livingston et al. "The Benefits and Costs of Treating Obesity Among Adults in the Medicaid Program" doi.org/10.2337/doci25-0005. Davidson et al. "Effectiveness of Using Patient-Defined Meal Sizes to Determine Bolus Doses of Insulin" doi.org/10.2337/doc25-0018 Ali et al. "Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity" doi.org/10.2337/doc25-0026 Masiano et al. "Type 2 Diabetes Treatment and Experience With Hospitalization in Older Adults: A Convergent Mixed-Methods Study" doi.org/10.2337/doc25-0009 Young et al. "The Critical Role of Diabetology Pharmacists in Improving Cardiovascular-Kidney-Metabolic Care and Outcome" doi.org/10.2337/doc25-0049 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

In this special series on Oral GLP-1 Receptor Agonists, Dr. Neil Skolnik will discuss the first of the GLP-1 RAs to receive FDA approval, Semaglutide. This special episode is sponsored with support from Novo Nordisk. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health W. Timothy Garvey, MD., Butterworth Professor and University Professor of Medicine in the Department of Nutrition Sciences at the University of Alabama at Birmingham. Selected references: Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Knop, Filip K et al. The Lancet, Volume 402, Issue 10403, 705 – 719 Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Wharton Sean et al. N Engl J Med 2025;393:1077-1087 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Lincoff, A Michael, et al. N Engl J Med 2023;389:2221-2232

In this special series on Weight Bias and Stigma our host, Dr. Neil Skolnik will discuss weight bias and stigma and its importance because weight bias and stigma have an important impact the experience of living with obesity, leads to measurable adverse outcomes, and when it is present in health care interactions it affects all subsequent care that a patient receives. This special episode is sponsored with support from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Sean Wharton, M.D., Medical Director of the Wharton Medical Clinic, Adjunct Professor McMaster University and York University. Patty Nece - Lawyer and Former Counsel for Regulations and Legislation at U.S. Department of Labor; Past Chair of the Obesity Action Coalition (OAC); Member National Academy of Sciences' Roundtable on Obesity Solutions; Member, World Obesity Federation Policy and Prevention Committee; Commissioner on The Lancet Commission on Obesity. Selected references: Weight stigma and bias: standards of care in overweight and obesity—2025. BMJ Open Diab Res Care 2025;13:e004962. doi:10.1136/ bmjdrc-2025-004962 Canadian Adult Obesity Clinical Practice Guidelines: reducing weight, bias, and obesity management, practice, and policy

In this special series on Automated Insulin Delivery our host, Dr. Neil Skolnik will discuss the benefits of Automated Insulin Delivery for people with Type 2 Diabetes. This special episode is supported by an independent educational grant from Insulet. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Davida Kruger, MSN, APN-BC,BC-ADM, Henry Ford Health, Detroit, Michigan. Past Chair of the American Diabetes Associations Research Foundation, Past president, Health Care and Education of the American Diabetes Association. Ashlyn Smith, MMS, PA-C, DFAAPA, LSC, Distinguished Fellow of the American Academy of PAs, Certified Diabetes Prevention Program Lifestyle Coach, Founder of ELM Endocrinology & Lifestyle Medicine, PLLC., Past President of the American Society of Endocrine Physician Assistants, Adjunct faculty at Midwestern University, Selected references: Automated Insulin Delivery in Adults With Type 2 Diabetes A Nonrandomized Clinical Trial. JAMA Network Open. 2025;8(2):e2459348. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med 2025;392:1801-12 Automated Insulin Pump in Type 2 Diabetes – Editorial - N Engl J Med 2025;392:1862-1863